Those with Parkinson’s disease have nerve cell damage in their brains which causes dopamine levels to drop. Dopamine is an essential neurotransmitter in the human brain, responsible for transmitting information among neurons and helping with the regulation of various functions, such as movement and emotional responses.
Parkinson’s Disease Studies
- Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.
- GPR3 and GPR6, novel molecular targets for cannabidiol
- Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures
- Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado
- Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms
- The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1-2 phosphorylation in 6-OHDA-lesioned rats
- The influence of cannabinoids on generic traits of neurodegeneration